| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 14 | 5 | +3,09 % | ||
| ORUKA THERAPEUTICS | 14 | - | +20,34 % | ||
| SAGIMET BIOSCIENCES | 9 | 1 | +47,20 % | ||
| LIGAND PHARMACEUTICALS | 8 | 2 | 0,00 % | ||
| ANAPTYSBIO | 7 | 2 | +17,07 % | ||
| FULCRUM THERAPEUTICS | 7 | - | -2,68 % | ||
| BIONTECH | 5 | 13 | -2,06 % | ||
| MIRUM PHARMACEUTICALS | 5 | 1 | +2,66 % | ||
| CORMEDIX | 4 | 10 | -3,31 % | ||
| RELAY THERAPEUTICS | 4 | 3 | -0,66 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:46 | Oruka surges as long-acting psoriasis drug shows early promise | 1 | BioPharma Dive | ||
| 18:34 | Oppenheimer hebt Kursziel für Sagimet an - Fokus auf Akne-Medikament | 1 | Investing.com Deutsch | ||
| 18:30 | Oppenheimer raises Sagimet stock price target on acne focus | 9 | Investing.com | ||
| 18:27 | Why Sagimet Biosciences Stock Is Soaring Today | 2 | The Motley Fool | ||
| 18:26 | Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive Moat | 1 | Insider Monkey | ||
| 18:26 | Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines | 2 | Insider Monkey | ||
| 18:26 | Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology | 1 | Insider Monkey | ||
| 18:18 | Guggenheim raises Oruka Therapeutics stock price target to $200 on trial data | 2 | Investing.com | ||
| 18:18 | Baird raises Mirum Pharmaceuticals stock price target on HDV data | 1 | Investing.com | ||
| 18:10 | Incyte vor Quartalszahlen: Povorcitinib-Hoffnung trifft auf Q1-Realität | 5 | Investing.com Deutsch | ||
| 17:58 | Studiendaten beflügeln: Raymond James erhöht Kursziel für Relay Therapeutics deutlich | - | Investing.com Deutsch | ||
| 17:54 | TD Cowen reiterates Intellia Therapeutics stock rating on phase 3 data | 24 | Investing.com | ||
| 17:54 | Raymond James raises Relay Therapeutics price target on trial data | 1 | Investing.com | ||
| 17:34 | IBRX: What Anktiva's Bladder Data Says About 2026 Sales | 8 | Zacks | ||
| 17:29 | Oruka Therapeutics Stock Surges 22% On Strong Psoriasis Trial Results | 1 | RTTNews | ||
| 17:28 | Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems | 1 | The Motley Fool | ||
| 17:18 | BTIG raises Oruka Therapeutics price target on trial results | 1 | Investing.com | ||
| 17:18 | BofA raises Intellia Therapeutics stock price target on HAE data | 14 | Investing.com | ||
| 17:10 | Ligand snaps up fellow biotech royalty aggregator Xoma for $739M | 2 | FiercePharma | ||
| 17:10 | Starke Studienergebnisse: BTIG verdoppelt Kursziel für Oruka Therapeutics | 7 | Investing.com Deutsch |